Levilimab vs tocilizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline

Levilimab · Ilsira

Marketed by Biocad

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT04227366 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 154 patients that measured ACR20 response, a validated rheumatoid arthritis disease-activity measure, at week 12. Levilimab combined with methotrexate produced a much higher response rate than placebo combined with methotrexate (68.6% vs 38.5%).

Reported efficacy

ACR 20 response (Week 12); Low disease activity (Week 24): ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). (met)

Result source: NCT04227366

tocilizumab · Actemra / RoActemra

Marketed by Roche and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT03155347 · Phase 3 · completed

This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.

Next expected readout: August 2028 · NCT05869955 (registry estimate)

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 (met)

Result source: NCT03155347

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevilimabtocilizumab
ACR2068.6% vs 38.5%a+30.1 vs placebowk 12NCT0422736660.9% vs 31.5%+29.4 vs placebo162 mg sc · wk 24 · n 437NCT01232569
8 other results
  • 56.3% vs 27% 8 mg/kg · wk 24 · n 398 · Phase 3 · primary NCT00106535
  • 50.6% vs 27% 4 mg/kg · wk 24 · n 399 · Phase 3 · primary NCT00106535
  • 54.5% vs 29.3% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 55.8% vs 24.7% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 49.1% vs 29.3% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 47.9% vs 24.7% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 52.9% vs 25% wk 24 · Phase 3 · primary NCT03155347
  • 50% vs 25% wk 24 · Phase 3 · primary NCT03155347
ACR50—Not posted · NCT0422736638.9% vs 19.8%+19.1 vs placebo8 mg/kg · wk 104 · n 398NCT00106535
5 other results
  • 36.4% vs 10.2% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 32.2% vs 9.7% 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • 37.6% vs 19.8% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 30.3% vs 10.2% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 25.1% vs 9.7% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
ACR70—Not posted · NCT0422736622.4% vs 12.2%+10.2 vs placebo8 mg/kg · wk 104 · n 398NCT00106535
5 other results
  • 20.1% vs 3.8% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 12.6% vs 2% 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • 24.3% vs 12.2% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 16.5% vs 3.8% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 11% vs 2% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
DAS28-CRP remission—Not posted · NCT04227366—Not posted · NCT00106548
HAQ-DI, change—Not posted · NCT04227366-0.5 vs -0.3−0.2 vs placebo162 mg sc · wk 24 · n 348NCT01232569
6 other results
  • -0.6 vs -0.5 8 mg/kg · wk 104 · n 231 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.4 8 mg/kg · wk 52 · n 263 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 4 mg/kg · wk 104 · n 218 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.4 4 mg/kg · wk 52 · n 235 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
Modified Sharp score, change—Not posted · NCT042273660.4 vs 2.0−1.6 vs placebo8 mg/kg · wk 104 · n 353NCT00106535
8 other results
  • 0.3 vs 1.1 8 mg/kg · wk 52 · n 348 · Phase 3 · primary NCT00106535
  • 0.6 vs 2.0 4 mg/kg · wk 104 · n 343 · Phase 3 · primary NCT00106535
  • 0.3 vs 1.1 4 mg/kg · wk 52 · n 339 · Phase 3 · primary NCT00106535
  • 0.6 vs 1.2 162 mg sc · wk 24 · n 391 · Phase 3 · secondary NCT01232569
  • 0.3 vs 1.6 8 mg/kg · wk 80 · n 353 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 8 mg/kg · wk 24 · n 334 · Phase 3 · secondary NCT00106535
  • 0.5 vs 1.6 4 mg/kg · wk 80 · n 343 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 4 mg/kg · wk 24 · n 327 · Phase 3 · secondary NCT00106535

ACR20

Levilimab
68.6% vs 38.5%a+30.1 vs placebowk 12NCT04227366
tocilizumab
60.9% vs 31.5%+29.4 vs placebo162 mg sc · wk 24 · n 437NCT01232569
8 other results
  • 56.3% vs 27% 8 mg/kg · wk 24 · n 398 · Phase 3 · primary NCT00106535
  • 50.6% vs 27% 4 mg/kg · wk 24 · n 399 · Phase 3 · primary NCT00106535
  • 54.5% vs 29.3% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 55.8% vs 24.7% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 49.1% vs 29.3% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 47.9% vs 24.7% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 52.9% vs 25% wk 24 · Phase 3 · primary NCT03155347
  • 50% vs 25% wk 24 · Phase 3 · primary NCT03155347

ACR50

Levilimab
—Not posted · NCT04227366
tocilizumab
38.9% vs 19.8%+19.1 vs placebo8 mg/kg · wk 104 · n 398NCT00106535
5 other results
  • 36.4% vs 10.2% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 32.2% vs 9.7% 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • 37.6% vs 19.8% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 30.3% vs 10.2% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 25.1% vs 9.7% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535

ACR70

Levilimab
—Not posted · NCT04227366
tocilizumab
22.4% vs 12.2%+10.2 vs placebo8 mg/kg · wk 104 · n 398NCT00106535
5 other results
  • 20.1% vs 3.8% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 12.6% vs 2% 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • 24.3% vs 12.2% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 16.5% vs 3.8% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 11% vs 2% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535

DAS28-CRP remission

Levilimab
—Not posted · NCT04227366
tocilizumab
—Not posted · NCT00106548

HAQ-DI, change

Levilimab
—Not posted · NCT04227366
tocilizumab
-0.5 vs -0.3−0.2 vs placebo162 mg sc · wk 24 · n 348NCT01232569
6 other results
  • -0.6 vs -0.5 8 mg/kg · wk 104 · n 231 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.4 8 mg/kg · wk 52 · n 263 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 4 mg/kg · wk 104 · n 218 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.4 4 mg/kg · wk 52 · n 235 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535

Modified Sharp score, change

Levilimab
—Not posted · NCT04227366
tocilizumab
0.4 vs 2.0−1.6 vs placebo8 mg/kg · wk 104 · n 353NCT00106535
8 other results
  • 0.3 vs 1.1 8 mg/kg · wk 52 · n 348 · Phase 3 · primary NCT00106535
  • 0.6 vs 2.0 4 mg/kg · wk 104 · n 343 · Phase 3 · primary NCT00106535
  • 0.3 vs 1.1 4 mg/kg · wk 52 · n 339 · Phase 3 · primary NCT00106535
  • 0.6 vs 1.2 162 mg sc · wk 24 · n 391 · Phase 3 · secondary NCT01232569
  • 0.3 vs 1.6 8 mg/kg · wk 80 · n 353 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 8 mg/kg · wk 24 · n 334 · Phase 3 · secondary NCT00106535
  • 0.5 vs 1.6 4 mg/kg · wk 80 · n 343 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 4 mg/kg · wk 24 · n 327 · Phase 3 · secondary NCT00106535
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Levilimab: 0 of 4 rows · tocilizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevilimabtocilizumab
Dropout rate—
57.7%Tocilizumaba
NCT01941095 · Phase 3 · other
show 49 more results
—Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
—Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
19.3%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—8 mg/kg
NCT00106535 · Phase 3 · combination
22.7%8 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
22.9%4 mg/kg
NCT00106535 · Phase 3 · combination
10.6%Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
9.4%Tocilizumab SC
NCT01194414 · Phase 3
—Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
—Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
3.6%
NCT01331837 · Phase 4
11.7%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
11.5%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT01717859 · Phase 4 · registry result, not featured evidence
3.8%
NCT01715831 · Phase 4 · registry result, not featured evidence
39.3%
NCT01149057 · Phase 4 · registry result, not featured evidence
—TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
3.6%TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
4.9%TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
55.9%
NCT01219933 · Phase 4 · registry result, not featured evidence
18.3%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
—8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
14.7%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
—
NCT01089023 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
3.5%
NCT00996203 · Phase 4 · registry result, not featured evidence
—
NCT02010216 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
14.3%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
68.2%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
53.6%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
14.5%
NCT01941940 · Phase 3 · registry result, not featured evidence
11.3%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
17.4%
NCT01668966 · Phase 3 · registry result, not featured evidence
14.1%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
13.5%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
16.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
—TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
18.2%
NCT01734993 · Phase 3 · registry result, not featured evidence
1.9%
NCT01951170 · Phase 3 · registry result, not featured evidence
20%
NCT01655381 · Phase 3 · registry result, not featured evidence
15%
NCT01988012 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs—
11.3%Tocilizumaba
NCT01941095 · Phase 3 · other
show 49 more results
—Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
—Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
10.5%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—8 mg/kg
NCT00106535 · Phase 3 · combination
—8 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
6.3%Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
4.4%Tocilizumab SC
NCT01194414 · Phase 3
—Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
—Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
—
NCT01331837 · Phase 4
3.9%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
3.8%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
9.3%
NCT01717859 · Phase 4 · registry result, not featured evidence
3.8%
NCT01715831 · Phase 4 · registry result, not featured evidence
9%
NCT01149057 · Phase 4 · registry result, not featured evidence
—TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
3.6%TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
1.2%TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
11.8%
NCT01219933 · Phase 4 · registry result, not featured evidence
8.3%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
—8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
5.5%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
—
NCT01089023 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
1.5%
NCT00996203 · Phase 4 · registry result, not featured evidence
—
NCT02010216 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
9.8%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
0%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
0.7%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
4.8%
NCT01941940 · Phase 3 · registry result, not featured evidence
4.7%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
—
NCT01668966 · Phase 3 · registry result, not featured evidence
4.6%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
5.4%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
6.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
—TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
9.1%
NCT01734993 · Phase 3 · registry result, not featured evidence
—
NCT01951170 · Phase 3 · registry result, not featured evidence
—
NCT01655381 · Phase 3 · registry result, not featured evidence
5%
NCT01988012 · Phase 3 · registry result, not featured evidence
Serious AEs—
—Tocilizumaba
NCT01941095 · Phase 3 · other
show 49 more results
7.6%Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
6.5%Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
8.8%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
25.3%8 mg/kg
NCT00106535 · Phase 3 · combination
—8 mg/kg
NCT00106535 · Phase 3 · combination
9.7%4 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
12.7%Tocilizumab IV
NCT01194414 · Phase 3
11.3%Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
13.9%Tocilizumab SC
NCT01194414 · Phase 3
12.5%Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
8.2%Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
10.1%Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
31.1%
NCT01331837 · Phase 4
3.1%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
5.3%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT01717859 · Phase 4 · registry result, not featured evidence
15.4%
NCT01715831 · Phase 4 · registry result, not featured evidence
24.8%
NCT01149057 · Phase 4 · registry result, not featured evidence
11.5%TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
1.2%TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
0%TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
4.9%TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
1.2%TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
—
NCT01219933 · Phase 4 · registry result, not featured evidence
5%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
19%8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
11.7%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
8.4%
NCT01089023 · Phase 4 · registry result, not featured evidence
5.7%8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
6%
NCT00996203 · Phase 4 · registry result, not featured evidence
0%
NCT02010216 · Phase 4 · registry result, not featured evidence
9.4%8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
9%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
14.3%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
5%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01941940 · Phase 3 · registry result, not featured evidence
9.3%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
9.5%
NCT01668966 · Phase 3 · registry result, not featured evidence
3.1%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
4.1%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
11.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
11.6%TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
18.2%
NCT01734993 · Phase 3 · registry result, not featured evidence
5.8%
NCT01951170 · Phase 3 · registry result, not featured evidence
6.7%
NCT01655381 · Phase 3 · registry result, not featured evidence
6%
NCT01988012 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs—
a
alanine aminotransferase increased 19.7%
aspartate aminotransferase increased 13.6%
leukopenia 12.1%
NCT01941095 · Phase 3 · combination
show 43 more results
alanine aminotransferase increased 29%
aspartate aminotransferase increased 25.8%
neutropenia 19.4%
NCT01941095 · Phase 3 · monotherapy
bronchitis 15.8%
cough 12.3%
nasopharyngitis 12.3%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
8 mg/kg
upper respiratory tract infection 24.3% (placebo 7.4%)
urinary tract infection 16.1% (placebo 5.1%)
hypertension 13.4% (placebo 3.1%)
NCT00106535 · Phase 3 · combination
4 mg/kg
upper respiratory tract infection 9.2% (placebo 7.4%)
hypertension 5.7% (placebo 3.1%)
urinary tract infection 5.7% (placebo 5.1%)
NCT00106535 · Phase 3 · combination
alanine aminotransferase increased 22.2%
upper respiratory tract infection 20.6%
aspartate aminotransferase increased 15.2%
NCT01194414 · Phase 3
upper respiratory tract infection 17.7%
alanine aminotransferase increased 15.6%
nasopharyngitis 14%
NCT01194414 · Phase 3
alanine aminotransferase increased 29.8%
aspartate aminotransferase increased 21.4%
upper respiratory tract infection 19.3%
NCT01194414 · Phase 3
upper respiratory tract infection 16.7%
alanine aminotransferase increased 14.6%
nasopharyngitis 14.6%
NCT01194414 · Phase 3
alanine aminotransferase increased 15.3% (placebo 6%)
upper respiratory tract infection 11.9% (placebo 6.4%)
aspartate aminotransferase increased 9.2% (placebo 4.6%)
NCT01232569 · Phase 3
alanine aminotransferase increased 14.3% (placebo 6%)
upper respiratory tract infection 12.5% (placebo 6.4%)
nasopharyngitis 9.5% (placebo 2.3%)
NCT01232569 · Phase 3
bronchitis 15.9%
upper respiratory tract infection 15.8%
nasopharyngitis 15.5%
NCT01331837 · Phase 4
nasopharyngitis 7%
diarrhoea 3.9%
alanine aminotransferase increased 2.3%
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 9.9%
alanine aminotransferase increased 6.9%
aspartate aminotransferase increased 6.9%
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis flare 38.9%
upper respiratory infection 38.9%
hypercholesterolemia 31.5%
NCT01717859 · Phase 4 · registry result, not featured evidence
respiratory tract infection nos 46.2%
musculoskeletal pain 30.8%
urinary tract infection 26.9%
NCT01715831 · Phase 4 · registry result, not featured evidence
alanine aminotransferase/aspartate aminotransferase elevations 32.4%
leukopenia 22.1%
upper respiratory tract infection 17.2%
NCT01149057 · Phase 4 · registry result, not featured evidence
hypertransaminasaemia 15.6%
hypercholesterolaemia 9.4%
leukopenia 7.3%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 9.6%
aphthous stomatitis 0%
hypercholesterolaemia 0%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 14.5%
aphthous stomatitis 3.6%
urinary tract infection 3.6%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 4.9%
aphthous stomatitis 0%
hypercholesterolaemia 0%
NCT01399697 · Phase 4 · registry result, not featured evidence
hypertransaminasaemia 12.2%
aphthous stomatitis 7.3%
hypercholesterolaemia 7.3%
NCT01399697 · Phase 4 · registry result, not featured evidence
sinusitis 8.3%
headache 6.7%
nausea 6.7%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
8 mg/kg
rheumatoid arthritis 47.6%
lower respiratory tract infection 42.9%
nasopharyngitis 38.1%
NCT01195272 · Phase 4 · registry result, not featured evidence
8 mg/kg
upper respiratory tract infection 11.1%
nasopharyngitis 10.5%
hypertension 8%
NCT01119859 · Phase 4 · registry result, not featured evidence
investigations 30.5%
blood and lymphatic system disorders 7.4%
infections and infestations 7.4%
NCT01089023 · Phase 4 · registry result, not featured evidence
8 mg/kg
urinary tract infection 11.4% (placebo 10%)
hypercholesterolemia 8.6% (placebo 10%)
elevated alt 5.7% (placebo 0%)
NCT01034397 · Phase 4 · registry result, not featured evidence
alanine aminotransferase increased 4.5%
transaminases increased 4%
respiratory tract infection 3%
NCT00996203 · Phase 4 · registry result, not featured evidence
drowsiness 8.7%
NCT02010216 · Phase 4 · registry result, not featured evidence
8 mg/kg
acute bronchitis 9.4%
leucopenia+lymphopenia 9.4%
hepatopathy 6.3%
NCT01010503 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15%
hypertension 12.8%
nausea 8.3%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
lower respiratory tract infection 28.6%
nasopharyngitis 23.8%
urinary tract infection 23.8%
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
nasopharyngitis 23.6%
diarrhoea 22.9%
alanine aminotransferase increased 22.1%
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
influenza 10.1%
cough 7%
bronchitis 6.6%
NCT01941940 · Phase 3 · registry result, not featured evidence
nasopharyngitis 23.3%
fatigue 12%
nausea 12%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 42.9%
dyslipidaemia 23.8%
upper respiratory tract infection 19%
NCT01668966 · Phase 3 · registry result, not featured evidence
transaminases increased 11.3%
upper respiratory tract infection 7%
urinary tract infection 7%
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
injection site erythema 8.1%
urinary tract infection 8.1%
back pain 5.4%
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
rheumatoid arthritis 13.7%
bronchitis 11.5%
rhinitis 9.4%
NCT02001987 · Phase 3 · registry result, not featured evidence
rheumatoid arthritis 18.6%
bronchitis 16.3%
ear infection 11.6%
NCT02001987 · Phase 3 · registry result, not featured evidence
bronchitis 45.5%
arthralgia 36.4%
urinary tract infection 27.3%
NCT01734993 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 28.8%
rheumatoid arthritis 21.2%
neutropenia 11.5%
NCT01951170 · Phase 3 · registry result, not featured evidence
bronchitis 40%
back pain 33.3%
asthenia 26.7%
NCT01655381 · Phase 3 · registry result, not featured evidence
neutropenia 12%
hepatic enzyme increased 11%
leukopenia 11%
NCT01988012 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 49 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tocilizumab

DAS28-ESR Remission 40% (n=80) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 53 more results
4.8% (n=21) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 1 participants as posted
10.7% (n=140) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 15 participants as posted
9.5% (n=21) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 2 participants as posted
24.3% (n=140) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 34 participants as posted
23.8% (n=21) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 5 participants as posted
37.9% (n=140) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 53 participants as posted
28.6% (n=21) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 participants as posted
47.1% (n=140) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 participants as posted
47.6% (n=21) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 10 participants as posted
51.4% (n=140) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 72 participants as posted
52.4% (n=21) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
53.6% (n=140) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 75 participants as posted
66.7% (n=21) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
54.3% (n=140) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 76 participants as posted
66.7% (n=21) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
52.1% (n=140) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 73 participants as posted
57.1% (n=21) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
57.1% (n=140) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
66.7% (n=21) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
57.1% (n=140) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
61.9% (n=21) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 13 participants as posted
57.9% (n=140) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 81 participants as posted
47.6% (n=21) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 10 participants as posted
57.1% (n=140) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
52.4% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
55.7% (n=140) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 78 participants as posted
57.1% (n=21) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
57.1% (n=140) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
82.6% (n=23) @ 28wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
90.6% (n=66) @ 28wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
87% (n=23) @ 28wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
83.1% (n=67) @ 28wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
81.8% (n=23) @ 32wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
89.1% (n=66) @ 32wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
78.3% (n=23) @ 32wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
82.1% (n=67) @ 32wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
90.5% (n=23) @ 36wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
76.9% (n=66) @ 36wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
86.4% (n=23) @ 36wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
86.4% (n=67) @ 36wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
85% (n=23) @ 40wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
81.3% (n=66) @ 40wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 40wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
81.8% (n=67) @ 40wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
94.7% (n=23) @ 44wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
87.3% (n=66) @ 44wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 44wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
78.8% (n=67) @ 44wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
100% (n=23) @ 48wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
89.1% (n=66) @ 48wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 48wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
72.7% (n=67) @ 48wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
76.6% (n=52) @ 24wk
NCT01951170 · Phase 3 · registry result, not featured evidence
DAS28-ESR -0.99 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 74 more results
-1.7 score @ 4wk
NCT01941095 · Phase 3 · other
-2.2 score @ 8wk
NCT01941095 · Phase 3 · other
-2.56 score @ 12wk
NCT01941095 · Phase 3 · other
-2.59 score @ 16wk
NCT01941095 · Phase 3 · other
-2.93 score @ 20wk
NCT01941095 · Phase 3 · other
-3.14 score @ 24wk
NCT01941095 · Phase 3 · other
-3.22 score @ 28wk
NCT01941095 · Phase 3 · other
-3.34 score @ 32wk
NCT01941095 · Phase 3 · other
-3.32 score @ 36wk
NCT01941095 · Phase 3 · other
-3.4 score @ 40wk
NCT01941095 · Phase 3 · other
-3.45 score @ 44wk
NCT01941095 · Phase 3 · other
-3.42 score @ 48wk
NCT01941095 · Phase 3 · other
-3.4 score @ 52wk
NCT01941095 · Phase 3 · other
-3.24 score @ 24wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-3.21 score @ 24wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
0.538 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-0.075 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-1.4 score @ 2wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-2.1 score @ 4wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-2.8 score @ 8wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-2.9 score @ 12wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-3.2 score @ 16wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-3.3 score @ 20wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-3.3 score @ 24wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-1.41 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-1.22 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-1.86 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-2.11 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-2.42 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-2.62 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-2.33 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-2.99 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-2.93 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.07 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.17 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.13 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.28 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.33 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.54 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.32 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.19 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.54 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.57 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.55 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.82 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.64 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.61 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.65 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.54 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.65 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.75 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.67 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-2.88 score
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-1.63 score
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-1.5 score @ 2wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-3.2 score @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-3.6 score @ 52wk
NCT01941940 · Phase 3 · registry result, not featured evidence
1.337 score @ 2wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
2.037 score @ 4wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
2.635 score @ 8wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
2.908 score @ 12wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
3.014 score @ 16wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
3.169 score @ 20wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
3.232 score @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-3.07 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-1.19 score @ 2wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-2.16 score @ 4wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-2.7 score @ 8wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.16 score @ 12wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.2 score @ 16wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.27 score @ 20wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.01 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.3 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-2.47 score @ 24wk
NCT01988012 · Phase 3 · registry result, not featured evidence
ACR20 19.8% (n=96) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01941095 · Phase 3 · other · converted to % from 19 participants as posted
show 50 more results
19.8% (n=96) @ 4wk*
NCT01941095 · Phase 3 · other · converted to % from 19 participants as posted
24% (n=96) @ 8wk*
NCT01941095 · Phase 3 · other · converted to % from 23 participants as posted
9.4% (n=96) @ 12wk*
NCT01941095 · Phase 3 · other · converted to % from 9 participants as posted
13.5% (n=96) @ 16wk*
NCT01941095 · Phase 3 · other · converted to % from 13 participants as posted
16.7% (n=96) @ 20wk*
NCT01941095 · Phase 3 · other · converted to % from 16 participants as posted
9.4% (n=96) @ 24wk*
NCT01941095 · Phase 3 · other · converted to % from 9 participants as posted
13.5% (n=96) @ 28wk*
NCT01941095 · Phase 3 · other · converted to % from 13 participants as posted
10.4% (n=96) @ 32wk*
NCT01941095 · Phase 3 · other · converted to % from 10 participants as posted
11.5% (n=96) @ 36wk*
NCT01941095 · Phase 3 · other · converted to % from 11 participants as posted
10.4% (n=96) @ 40wk*
NCT01941095 · Phase 3 · other · converted to % from 10 participants as posted
12.5% (n=96) @ 44wk*
NCT01941095 · Phase 3 · other · converted to % from 12 participants as posted
13.5% (n=96) @ 48wk*
NCT01941095 · Phase 3 · other · converted to % from 13 participants as posted
15.6% (n=96) @ 52wk*
NCT01941095 · Phase 3 · other · converted to % from 15 participants as posted
69.4% (n=558) @ 24wk
NCT01194414 · Phase 3
73.4% (n=537) @ 24wk
NCT01194414 · Phase 3
28.6% (n=21) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 participants as posted
16.4% (n=140) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 23 participants as posted
28.6% (n=21) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 participants as posted
48.6% (n=140) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 68 participants as posted
52.4% (n=21) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
49.3% (n=140) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 69 participants as posted
47.6% (n=21) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 10 participants as posted
59.3% (n=140) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 83 participants as posted
61.9% (n=21) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 13 participants as posted
59.3% (n=140) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 83 participants as posted
71.4% (n=21) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 15 participants as posted
61.4% (n=140) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 86 participants as posted
71.4% (n=21) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 15 participants as posted
64.3% (n=140) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 90 participants as posted
66.7% (n=21) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
62.1% (n=140) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 participants as posted
61.9% (n=21) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 13 participants as posted
63.6% (n=140) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 participants as posted
57.1% (n=21) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
65.7% (n=140) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 92 participants as posted
61.9% (n=21) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 13 participants as posted
65% (n=140) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 91 participants as posted
57.1% (n=21) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
62.9% (n=140) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 88 participants as posted
57.1% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
62.1% (n=140) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 participants as posted
57.1% (n=21) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
62.9% (n=140) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 88 participants as posted
20.3% (n=150) @ 2wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
40.3% (n=150) @ 4wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
58.1% (n=150) @ 8wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
69.9% (n=150) @ 12wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
71.5% (n=150) @ 16wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
78.9% (n=150) @ 20wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
82.6% (n=150) @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
SDAI -3.41 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 84 more results
-6.54 score @ 4wk
NCT01941095 · Phase 3 · other
-8.72 score @ 8wk
NCT01941095 · Phase 3 · other
-11.07 score @ 12wk
NCT01941095 · Phase 3 · other
-13.47 score @ 16wk
NCT01941095 · Phase 3 · other
-13.88 score @ 20wk
NCT01941095 · Phase 3 · other
-14.08 score @ 24wk
NCT01941095 · Phase 3 · other
-15.37 score @ 28wk
NCT01941095 · Phase 3 · other
-16.09 score @ 32wk
NCT01941095 · Phase 3 · other
-15.61 score @ 36wk
NCT01941095 · Phase 3 · other
-14.86 score @ 40wk
NCT01941095 · Phase 3 · other
-16.31 score @ 44wk
NCT01941095 · Phase 3 · other
-16.47 score @ 48wk
NCT01941095 · Phase 3 · other
-17.35 score @ 52wk
NCT01941095 · Phase 3 · other
2.511 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
0.248 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-15.37 score @ 2wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-20.32 score @ 4wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-25.89 score @ 8wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-26.19 score @ 12wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-29.03 score @ 16wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-28.47 score @ 20wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-28.93 score @ 24wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-9.8 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-6.94 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-12.64 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-13.92 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-19.75 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-17.21 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-14.65 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-20.26 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-19.48 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-21.16 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-23.67 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-20.5 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-24.31 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-23.48 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-24.87 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-23.26 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-22.98 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-24.94 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.32 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-24.65 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.29 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-25.46 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.71 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.08 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.83 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.13 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.45 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.15 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.5 score @ 2wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-38.9 score @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-39.3 score @ 52wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-6.2 score @ 2wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-11.3 score @ 4wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-14.4 score @ 8wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-17.2 score @ 12wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-18.5 score @ 16wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-19.7 score @ 20wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-19.9 score @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-20.45 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-19.5 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-27.86 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-24.34 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-32.61 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-29.34 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-36.23 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-30.95 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-37.82 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-32.66 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-36.79 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-33.95 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-41.38 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-34.8 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-8.54 score @ 2wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-14.23 score @ 4wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-20.2 score @ 8wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-23.09 score @ 12wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-24.31 score @ 16wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-24.41 score @ 20wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-22.45 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-23.29 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-31.6 score @ 24wk
NCT01951170 · Phase 3 · registry result, not featured evidence
-21.41 score @ 24wk
NCT01988012 · Phase 3 · registry result, not featured evidence
TJC28 -1.3 tender joints @ 2wk
absolute change · tender joints
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 13 more results
-3.26 tender joints @ 4wk
NCT01941095 · Phase 3 · other
-4.97 tender joints @ 8wk
NCT01941095 · Phase 3 · other
-5.82 tender joints @ 12wk
NCT01941095 · Phase 3 · other
-6.39 tender joints @ 16wk
NCT01941095 · Phase 3 · other
-7.03 tender joints @ 20wk
NCT01941095 · Phase 3 · other
-7.72 tender joints @ 24wk
NCT01941095 · Phase 3 · other
-7.91 tender joints @ 28wk
NCT01941095 · Phase 3 · other
-8.38 tender joints @ 32wk
NCT01941095 · Phase 3 · other
-8.28 tender joints @ 36wk
NCT01941095 · Phase 3 · other
-8.22 tender joints @ 40wk
NCT01941095 · Phase 3 · other
-8.63 tender joints @ 44wk
NCT01941095 · Phase 3 · other
-8.26 tender joints @ 48wk
NCT01941095 · Phase 3 · other
-8.75 tender joints @ 52wk
NCT01941095 · Phase 3 · other
SJC28 -1.82 swollen joints @ 2wk
absolute change · swollen joints
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 13 more results
-3.08 swollen joints @ 4wk
NCT01941095 · Phase 3 · other
-4.71 swollen joints @ 8wk
NCT01941095 · Phase 3 · other
-5.24 swollen joints @ 12wk
NCT01941095 · Phase 3 · other
-5.79 swollen joints @ 16wk
NCT01941095 · Phase 3 · other
-6.06 swollen joints @ 20wk
NCT01941095 · Phase 3 · other
-6.6 swollen joints @ 24wk
NCT01941095 · Phase 3 · other
-6.65 swollen joints @ 28wk
NCT01941095 · Phase 3 · other
-6.73 swollen joints @ 32wk
NCT01941095 · Phase 3 · other
-6.76 swollen joints @ 36wk
NCT01941095 · Phase 3 · other
-6.91 swollen joints @ 40wk
NCT01941095 · Phase 3 · other
-6.82 swollen joints @ 44wk
NCT01941095 · Phase 3 · other
-6.63 swollen joints @ 48wk
NCT01941095 · Phase 3 · other
-6.98 swollen joints @ 52wk
NCT01941095 · Phase 3 · other
Corticosteroid Dose Reduction 48.6% (n=37) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT01941095 · Phase 3 · other
HAQ-DI -0.08 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 37 more results
-0.54 score @ 24wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-1.33 score @ 52wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
0.167 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-0.087 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-0.4 score @ 24wk
NCT01149057 · Phase 4 · registry result, not featured evidence
-0.4 score @ 48wk
NCT01149057 · Phase 4 · registry result, not featured evidence
-0.4 score @ 72wk
NCT01149057 · Phase 4 · registry result, not featured evidence
-0.5 score @ 96wk
NCT01149057 · Phase 4 · registry result, not featured evidence
0.08 score @ 28wk
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
0 score @ 28wk
NCT01399697 · Phase 4 · registry result, not featured evidence
1.11 score @ 24wk
NCT00996203 · Phase 4 · registry result, not featured evidence
-0.1 score @ 2wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.3 score @ 4wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.5 score @ 8wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.5 score @ 12wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.6 score @ 16wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.6 score @ 20wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.6 score @ 24wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-0.2 score @ 2wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-0.4 score @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-0.5 score @ 52wk
NCT01941940 · Phase 3 · registry result, not featured evidence
1.39 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
1.18 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
1.2 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
1.05 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
1.1 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
0.95 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
0.99 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
0.91 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
0.99 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
0.87 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
0.88 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
0.83 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
0.85 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
0.82 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-0.78 score @ 24wk
NCT01951170 · Phase 3 · registry result, not featured evidence
-0.34 score @ 24wk
NCT01988012 · Phase 3 · registry result, not featured evidence
ACR50 32.2% (n=398) vs 9.7% (n=393) placebo @ 24wk8 mg/kg
responder rate · % of participants
NCT00106535 · Phase 3 · combination
show 5 more results
36.4% (n=398) vs 10.2% (n=393) placebo @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
38.9% (n=398) vs 19.8% (n=393) placebo @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
25.1% (n=399) vs 9.7% (n=393) placebo @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
30.3% (n=399) vs 10.2% (n=393) placebo @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
37.6% (n=399) vs 19.8% (n=393) placebo @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination
ACR70 12.6% (n=398) vs 2% (n=393) placebo @ 24wk8 mg/kg
responder rate · % of participants
NCT00106535 · Phase 3 · combination
show 5 more results
20.1% (n=398) vs 3.8% (n=393) placebo @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
22.4% (n=398) vs 12.2% (n=393) placebo @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
11% (n=399) vs 2% (n=393) placebo @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
16.5% (n=399) vs 3.8% (n=393) placebo @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
24.3% (n=399) vs 12.2% (n=393) placebo @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination
Swollen Joint Count -9 vs -2.9 placebo count @ 24wk8 mg/kg
absolute change · count
NCT00106535 · Phase 3 · combination
show 5 more results
-10.2 vs -2.5 placebo count @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
-11.3 vs -3.5 placebo count @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
-7.9 vs -2.9 placebo count @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
-8 vs -2.5 placebo count @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
-9 vs -3.5 placebo count @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination
Tender Joint Count -14.2 vs -4.8 placebo count @ 24wk8 mg/kg
absolute change · count
NCT00106535 · Phase 3 · combination
show 5 more results
-15.6 vs -4.1 placebo count @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
-17.7 vs -5.9 placebo count @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
-12.2 vs -4.8 placebo count @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
-12.3 vs -4.1 placebo count @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
-13.6 vs -5.9 placebo count @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination

+ 596 further endpoints in the CSV export.

COVID-19

Shared mechanism: IL-6 receptor · full COVID-19 pipeline

Levilimab · Ilsira

Marketed by Biocad

Phase 3 in COVID-19monoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

tocilizumab · Actemra / RoActemra

Marketed by Roche and partners

Approved in COVID-19monoclonal antibody
Partial signal

NCT04381936 · Phase 3 · recruiting

Patients were randomly assigned to tocilizumab or usual care alone, but there was no placebo and neither patients nor doctors were blinded. The primary endpoint, death from any cause within 28 days, is objective and was significantly lower with tocilizumab in 4116 patients (rate ratio 0.85, p=0.0028).

Next expected readout: December 2026 · NCT04363853 (registry estimate)

Reported efficacy

Time to Hospital Discharge or "Ready for Discharge" up to Day 28: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) (missed)

Result source: NCT04409262

Results for COVID-19

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Levilimab: no structured comparison results are available for COVID-19.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

tocilizumab
Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) NCT04372186 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4) (Day 28): Tocilizumab (TCZ) mITT Arm — 1: 56.5 Percentage of Participants; 2: 2 Percentage of Participants; 3: 4.8 Percentage of Participants; 4: 2 Percentage of Participants; 5: 8.8 Percentage of Participants; 6: 6.1 Percentage of Participants; 7: 19.7 Percentage of Participants | Placebo Modified Intent-to-Treat (mITT) Arm — 1: 49.3 Percentage of Participants; 2: 5.6 Percentage of Participants; 3: 2.8 Percentage of Participants; 4: 6.9 Percentage of Participants; 5: 9.7 Percentage of Participants; 6: 6.3 Percentage of Participants; 7: 19.4 Percentage of Participants NCT04320615 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) NCT04409262 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levilimab's landscape · tocilizumab's landscape